Abstract A vaccine consisting of rhesus cytomegalovirus (RhCMV) pp65-2, gB and IE1 expressed via modiWed vaccinia Ankara (MVA) was evaluated in rhesus macaques with or without prior priming with expression plasmids for the same antigens. Following two MVA treatments, comparable levels of anti-gB, pp65-2 and neutralizing antibody responses, and pp65-2-and IE1-speciWc cellular immune responses were detected in both vaccinated groups. Similar reductions in plasma peak viral loads were observed in these groups compared to untreated controls. This study demonstrates the immunogenicity and protective eYcacy of rMVA-based RhCMV subunit vaccines in a primate host and warrants further investigation to improve the eYcacy of subunit vaccines against CMV.
Introduction
Development of an eVective vaccine for human cytomegalovirus (HCMV) has been designated a "level 1" priority by the Institute of Medicine because of the devastating impact of congenital infection by HCMV which can have lifelong consequences [19] . The strict species-speciWcity of the virus requires assessment of vaccine strategies in a cognate animal model. Rhesus CMV (RhCMV) infection of rhesus macaques (Macaca mulatta-Mmu) strongly recapitulates HCMV infection in humans in terms of the similarity of viral genome, persistence, pathogenesis and host immune responses [2-4, 26, 27] , therefore, it represents a clinically relevant model to evaluate HCMV vaccine strategies.
Measurement of natural immunity to HCMV supports targeting the predominant neutralizing antibody response antigen gB and the strongly recognized cellular immunogens pp65 and IE1 as the optimal antigens in a vaccine formulated to prevent infection and control disease [28] . Previously, a study in Mmu demonstrated that immunization with DNA vaccines expressing RhCMV pp65-2 and truncated gB with deletion of transmembrane and intracellular domains (gB ) stimulated antigen-speciWc CD8+ T cell and antibody responses and provided limited protection against challenge [25] . A notable observation of this study was that a combination of DNA priming administered Wve times in 50 weeks followed by a heterologous boost (in this case, by the virus challenge) stimulated a rapid and profound increase in neutralizing antibody titers. In this report, we compared an approach in which recombinant modiWed vaccinia Ankara (rMVA) expressing RhCMV pp65-2, gB and IE1 antigens was administered twice to Mmu versus an identical schedule of rMVA administration preceded by a single DNA prime. Our primary goal was to establish whether these sub-unit vaccines are eVective for controlling an experimentally applied CMV infection and to test whether DNA priming enhances the eVectiveness of rMVA to stimulate protective immunity in this model.
Results

RhCMV-rMVA construction and expression
As a Wrst step, the genes encoding RhCMV 68-1 pp65-2 and gB were ampliWed from previously described plasmid expression vectors [25, 27] and engineered into the pZWIIA MVA transfer vector (Rh-gB-pp65-pZWIIA, Fig. 1a ), using established protocols [21] . Similarly, the RhCMV IE1 gene was ampliWed from a plasmid (pND/IE1) containing the cDNA (exons 1-4) for the RhCMV 68-1 IE1 [11] and engineered into the pLW51 MVA transfer vector (Rh IE1-pLW51, [22] ).
rMVA expressing either both RhCMV gB and pp65-2 (Rh gB-pp65-MVA) or IE1 alone (Rh IE1-MVA) was generated on BHK-21 cells via homologous recombination.
The protein expression levels for RhCMV gB, pp65-2 and IE1 in infected BHK-21 cells were conWrmed by Western blot using polyclonal antibodies to RhCMV gB, pp65-2, and IE1 by chemiluminescence detection (ECL, Amersham Pharmacia Biotech, Buckinghamshire, UK) (Fig. 1b) .
Although the genetic stability of the rMVA constructs was not directly evaluated, previous work using the same recombination plasmid pZWIIA to express HCMV soluble gB and/ or pp65 and IE1 exon-4 demonstrated that the resultant rMVA constructs were stable through four passages [20, 21] . The genetic instability of rMVA that has been observed usually happens when attempting to express certain integral membrane proteins at high levels, which may be due to the toxicity of over-expressed proteins [23] . The genetic stability of rMVA expressing membrane proteins can be enhanced after truncating the cytoplasmic domain [22, 23] . In this report, we used the same strategies and methods to construct the rMVAs expressing RhCMV truncated gB, pp65-2 and IE1. RhCMV gB, pp65-2 and IE1 are homologues of HCMV gB, pp65 and IE1 and the results in Fig. 1b conWrm expression of the foreign inserts. Aliquots of the same rMVA stocks used to demonstrate expression in infected tissue culture cells ( Fig. 1) were used to infect rhesus macaques.
Vaccination-induced immune responses
Six age-matched RhCMV-seronegative Mmu (2 years of age) were divided into three groups-DNA prime/rMVA/ 
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rMVA boost (DNA/rMVA), rMVA prime/rMVA boost (rMVA) and untreated control. Initially, DNA/rMVA animals were immunized intramuscularly and intradermally with a mixture of three plasmids (in pND vector [13] ) expressing RhCMV pp65-2, gB , and IE1 at week 0, following a previously published protocol [25] . Subsequently, all the DNA/rMVA and rMVA animals were injected intramuscularly with a mixture of Rh gB-pp65-MVA and Rh IE1-MVA (5 £ 10 8 pfu of each) at weeks 6 and 12 ( Fig. 2) . The elicited immune responses were measured by antigenspeciWc ELISA, an EGFP-Xuorescence intensity reductionneutralizing assay using an EGFP-RhCMV [6] , and intracellular cytokine staining (ICS). The ICS was performed as previously described protocols [5] to detect the frequency of CD4+ and CD8+ T cells that express IFN-or TNF-upon re-stimulation with a pool of overlapping peptides (15-mers overlapping by 11 amino acids) comprising full-length IE1 or pp65-2 antigen [26] . BrieXy, freshly isolated 1.0 £ 10 6 peripheral blood monocytes (PBMCs) were stimulated for 6 h with the peptide pool or medium in the presence of monoclonal antibodies to CD28 and CD49d. Brefeldin A was added to the culture for the Wnal 5 h of stimulation. SEB stimulated PBMCs were used as positive control. The stimulated cells were Wrst surface stained with conjugated antibodies to CD3 and CD8, or CD3 and CD4 for 30 min at 4°C. After Wxation and permeabilization, the cells were incubated with conjugated anti-cytokine monoclonal antibodies for 30 min at 4°C. The stained cells were then washed, and resuspended in 1% paraformaldehyde. Three hundred thousand lymphocyte events were collected on a FACS ARIA instrument (Becton-Dickinson). Data were analyzed using Flowjo software (version 8.1, Treestar, Ashland, OR).
DNA/rMVA and rMVA animals exhibited diVerent kinetics of antigen-speciWc and neutralizing antibody responses (Fig. 3) . As expected, single DNA immunization was not eVective by itself, but eVectively served to prime the animals for rMVA boosting (0-6 weeks, Fig. 3 ). Following the Wrst rMVA vaccination (6-12 weeks, Fig. 3 ), both DNA/ rMVA animals generated higher levels of anti-gB, pp65-2 and IE1 antibodies and 50% neutralizing titers (NT 50 , 527 and 108, respectively) than Mmu receiving rMVA without DNA priming (Fig. 3) . The two Mmu, only receiving rMVA, had low but detectable anti-gB responses and only one exhibited demonstrable NT 50 (Animal #4: 55) (Fig. 3) . Anti-gB and pp65-2 antibody levels and NT 50 rose sharply in both groups after the second rMVA immunization such that there were no diVerences between the two vaccine groups (12-18 weeks, Fig. 3 ). For the DNA/rMVA animals, the second rMVA boost stimulated peak anti-gB and antipp65-2 antibody responses within 1 week to levels higher than those observed after the Wrst boost at weeks 7-8, but not peak IE1 antibody and NT 50 (185 and 77, respectively). In contrast, the NT 50 in the rMVA group were appreciably higher than those observed after the Wrst rMVA immunization (294 and 122, respectively). rMVA immunization alone did not induce detectable anti-IE1 antibodies (Fig. 3) .
IE1-and pp65-2-speciWc CD4+ and CD8+ T cells were also detected in DNA/rMVA and rMVA animals with diVerent kinetics and magnitudes (Fig. 4) . DNA priming followed by rMVA boosting generated both pp65-2-and IE1-speciWc CD4+ and CD8+ T cells mostly at 1-2 weeks after the Wrst MVA booster, when a positive response was deWned as a 0.01% increase of each stained cell population compared to the pre-vaccination baseline. The second rMVA immunization only stimulated transient increases prior to challenge. For the rMVA group, IE1-and pp65-2-speciWc CD4+ and CD8+T cell responses in both animals were frequently detectable after the second rMVA immunization with the peak responses at week 14 or 18.
Plasma viral loads post-challenge
To evaluate the protective eYcacy of the two vaccine strategies, all the animals were challenged intravenously (IV, 2.0 £ 10 5 pfu) and subcutaneously (SC, 6 £ 10 5 pfu) with RhCMV 68-1 6 weeks after the second rMVA vaccination. 
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The plasma viral DNA loads were evaluated by real-time PCR [12] (Fig. 5a ). The reduction levels of peak viral loads in vaccines were calculated as (1 ¡ peak viral loads of vaccinee/peak viral loads of control animal) £ 100%. All four vaccinees exhibited diVerent levels of reduction in peak plasma RhCMV genome copy numbers compared to the controls (Fig. 5b) . One animal in each vaccine group (animals #2 and #3) had modest reductions (25.5-77.6%), while the other animal in each group (animals #1 and #4) had profound reductions (90.8-98.9%). Both of these latter animals were the same animals that had the higher NT 50 titers at 1 week after the second rMVA immunization and the time of challenge. Although statistical tests did not show a signiWcant correlation between the reduction levels of peak plasma viral loads and NT 50 titers at 1 week after the second rMVA immunization (Spearman r = 0.80, P = 0.33) and at the time of challenge (Spearman r = 0.80, P = 0.33) in these four vaccinees, this may be due to the small numbers of Mmu. All four vaccinated animals initially cleared virus from plasma by day 10, compared to days 13 and 17 for the two control monkeys (Fig. 5a ). Transient detection of RhCMV in plasma (less than 3.5 £ 10 3 copy number/ml) was noted for two of the vaccinees and one of the control animals (data not shown). In addition to plasma viral loads, skin biopsies of two sites of RhCMV inoculation (SC) were obtained on days 7 and 10 post-challenge to evaluate RhCMV replication at local inoculation sites. IE1-expressing cells in skin tissue slides were analyzed by immunohistochemstry. No signiWcant diVerences were observed between either the vaccinated and control groups (data not shown).
Immune responses post-challenge
All the vaccinees exhibited vigorous memory antibody responses post-challenge. These included anti-IE1 antibodies in the rMVA animals, which had no detectable antibodies prior to challenge (Fig. 3) . The relative increases in NT 50 of DNA/rMVA and rMVA animals at 1 and 2 weeks post challenge, compared to the time of challenge, were 24 to 44-fold and 101 to 453-fold, respectively (Fig. 3) . It was also noted that the NT 50 of DNA/rMVA animals at 2 weeks post-challenge were approximately two-to Wvefold above those of the rMVA animals. The normative range of NT 50 in long-term RhCMV seropositive macaques is 231-3,348 (N = 24, mean 973, median 833) (unpublished data). DNA/ rMVA and rMVA/rMVA animals produced comparable NT 50 at 1-week post-challenge and higher NT 50 at 2-week post-challenge as compared to long-term naturally infected Mmu, whereas the control animals had comparable NT 50 after 4 weeks post-challenge. RhCMV challenge stimulated a rapid increase in the frequencies of IE1-and pp65-2-speciWc CD8+ T cells in one of the DNA/rMVA treated MMu (animal #2) and the frequency of pp65-2-speciWc CD8+ T (Fig. 4) . The frequencies were comparable to or higher than those observed in two unvaccinated naturally RhCMV-seropositive animals, suggesting a memory T cell response in these animals. One unvaccinated control produced a very high frequency of IE1-speciWc CD8 + T cells at 7 weeks of challenge.
Discussion
In this report, we demonstrate that rMVA, either given as the sole vaccine or part of a heterologous prime/boost, can result in a dramatic decrease in viral load after RhCMV challenge in the Mmu model. Noteworthy was the need for only a single application of DNA to eVectively prime the 
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Weeks immune system for a heterologous boosting to produce higher levels of immunogenicity than observed with three DNA applications without viral boosting [20] . ModiWed vaccinia Ankara has been established as a safe and potent antigen delivery system. Promising data obtained from both nonhuman primates and clinical trials have shown that a combination of DNA prime and rMVA boost is eVective in stimulating eVective cellular immune responses and providing high protective eYcacy against HIV/SIV and malaria infection [7] . In this study, following the Wrst rMVA boosting, the monkeys primed with only a single application of DNA plasmids elicited earlier and stronger antibody and cellular immune responses than those without priming. However, similar magnitudes of anti-gB, pp65-2 and neutralizing antibodies and IE1-and pp65-2-speciWc CD4+ and CD8+ T cells were detected in both vaccinated groups after the second rMVA boost, with the exception of anti-IE1 antibodies, which were not detectable in rMVA animals.
Based on the level of IE1 expression in infected tissue culture cells (Fig. 1b) , it was somewhat surprising that rMVA immunization in the absence of DNA priming did not stimulate detectable antibody responses. However, the results were not unprecedented. Other studies have shown that a recombinant canarypox expressing HCMV gB did not stimulate immune responses in vaccinated humans, despite expression both in vitro and in small animals (mice and guinea pigs) [1, 10] . Comparable to our study, the canarypox construct did prime the immune system as demonstrated by the memory response generated after infection with the live attenuated Towne vaccine. In our study, prior immunization with DNA or RhCMV infection post rMVA vaccination similarly demonstrated that RhCMV IE1 was recognized in vivo in the context of rMVA.
Both approaches provided comparable protection against challenge. It was also noted that the frequencies of pp65-2-and IE1-speciWc CD4+ and CD8+ T cells in both vaccine groups generally were low, and strong memory T cell responses were only found in one animal in each vaccination group post-challenge. The reasons for the relatively low level of IE1-and pp65-2-speciWc T cell responses in this study are unknown. Other studies have demonstrated readily detectable levels of T cell responses to these RhCMV proteins in naturally infected or vaccinated Mmu [25, 26] . Naturally infected Mmu with IE1 and pp65-2 responses were included as positive controls for all of the cellular immune assays. Future studies will address whether augmentation of vaccine-induced responses to IE1 and pp65-2 correlate with increased protection against RhCMV challenge.
An observation of interest in this study was the apparent inXuence of neutralizing antibody on the containment of viral challenge in which the levels of peak plasma viral load reduction were related to the levels of neutralizing antibodies prior to challenge. Although a larger numbers of Mmu are needed to conWrm this observation, it further indicates the protective role of neutralizing antibodies against CMV [14, 17, 18, 24] and a gB-based vaccine strategy [15, 17, 25] . Natural immunity studies have suggested that a vaccine that stimulates immunity equivalent to levels associated with natural infection could reduce the morbidity due to congenital CMV infection by »80% [8, 9] . While the employment of either DNA/rMVA or rMVA to deliver RhCMV gB did not induce a relevant natural level, longlived neutralizing antibody response, other approaches including co-administration of GM-CSF, an adjuvant for the induction of NT [16] , either expressed via DNA or MVA are being explored.
In summary, this study for the Wrst time demonstrates the capacity of rMVA-based CMV vaccines to induce CMVspeciWc antibody and cellular immune responses in Mmu, and the protective eYcacy in reducing plasma viral loads following challenge. The data highlight the potential of rMVA-based CMV vaccines for humans and warrant continuing investigation of the DNA/rMVA approach in a larger number of Mmu to further test the possibility that subunit vaccines can interrupt horizontal transmission.
